Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 938 vs Aflibercept in Neovascular Age-related Macular Degeneration
NCT07614776Phase 3Recruiting
- Sponsor
- Amgen
- Start
- May 2026
- Primary completion
- Jul 2027
- Countries
- 9
01
Overview
A Phase 3 trial of 9MW0813 in neovascular age-related macular degeneration (NVAMD), sponsored by Amgen. Started May 2026; status: recruiting.
02
Drugs
9MW0813
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07614776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07614776.